Risk of New Onset Type Ii Dm in MDD Patients Receiving Second-Generation Antipsychotics Treatment: A Nationwide Cohort Study

Abstract

This study indicated that there is no significant difference in the risk of developing type II DM between MDD patients with and without SGA exposure. More studies focused on the benefit-risk assessment of SGA treatment in patients with MDD are warranted.

Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies

“…Twenty studies reported the results of potential determinants other than the specific antipsychotic of the occurrence of diabetes (Supplementary Table 5) [ 14 – 17 , 19 – 28 , 30 , 31 , 33 , 36 – 38 ]. The factors most frequently reported as being associated with the occurrence of diabetes were age [ 14 – 16 , 21 , 36 – 38 ], nonwhite race [ 15 , 21 , 24 ], length of exposure [ 16 , 17 , 25 , 33 ], obesity/body mass index (BMI) [ 15 , 16 , 19 , 20 , 23 , 26 , 27 , 31 ], hypertension [ 19 , 20 , 26 , 27 , 36 ], dyslipidemia [ 20 , 21 , 26 , 36 , 37 ], and treatment with concomitant medications, such as beta-blockers [ 15 – 17 , 24 , 31 ]; thiazides [ 15 , 16 , 24 , 31 ]; angiotensin-converting enzyme inhibitors [ 24 ]; antihypertensives [ 38 ]; lipid-lowering drugs [ 38 ]; specific lipid-lowering drugs, including fibrates [ 31 ] and statins [ 15 , 31 ]; and selective serotonin reuptake inhibitors (SSRIs) [ 15 , 24 ]. Regarding the type of psychiatric diagnosis, some studies found an increased risk of occurrence of diabetes for those with schizophrenia [ 16 , 30 ...…”

“…2 for binary outcomes and Supplementary Fig. 3 for time-to-event outcomes [35][36][37][38][39][40]. Among these latter studies, Rajkumar et al [39], in young adults with schizophrenia, showed that the three individual antipsychotics analyzed, namely, clozapine, olanzapine, and aripiprazole, were associated with a significantly increased likelihood of developing diabetes compared with antipsychotic-naïve patients.…”

“…Note: a study conducted by Jerrell et al [46] reported that risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole were not associated with an increased likelihood of dyslipidemia, but the authors did not report the specific results for these SGAs. [20,21,26,36,37], and treatment with concomitant medications, such as beta-blockers [15-17, 24, 31]; thiazides [15,16,24,31]; angiotensin-converting enzyme inhibitors [24]; antihypertensives [38]; lipid-lowering drugs [38]; specific lipid-lowering drugs, including fibrates [31] and statins [15,31]; and selective serotonin reuptake inhibitors (SSRIs) [15,24]. Regarding the type of psychiatric diagnosis, some studies found an increased risk of occurrence of diabetes for those with schizophrenia [16,30,31], bipolar disorder [30], and posttraumatic stress disorder [30], while others found that major affective disorders were associated with a reduced risk of occurrence of diabetes [17]; finally, some studies did not find that the type of diagnosis was a factor associated with the occurrence of diabetes [14,20,23].…”